Placeholder canvas

September 2021 Top Biopharma Deal: REGENXBIO – AbbVie for RBX-314 for wet AMD, diabetic retinopathy

Oct 7, 2021 | Deal of the Month, Partnership Deals

September 2021 Top Biopharma Deal Upfront
REGENXBIO development and commercialization deal with AbbVie for RGX-314

Highlighted Deal Financial Comps

Date Announced:

September 13, 2021

Total Deal Value:

$1,750M

Upfront Cash:

$370M

Upfront Equity:

n/a

Option Payments:

n/a

Total Milestones:

$1,380M (Dev., Reg., and Sales)

Royalties:

Tiered ex-U.S.

Cost & Profit Split:

50% in U.S.

Deal Synopsis

The Asset:

Phase II RGX-314 for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other chronic retinal diseases.

Deal Structure:

Development and Commercial License

Partnership Features:

Co-Development and co-promotion option.

Deal Details:

  • REGENXBIO granted AbbVie exclusive, worldwide rights to develop and commercialize RGX-314 for the treatment of wet AMD, diabetic retinopathy, and other chronic retinal diseases.
  • REGENXBIO will be responsible for completion of the ongoing trials.
  • AbbVie and REGENXBIO will share costs on additional trials, including the planned second pivotal trial evaluating subretinal delivery for the treatment of wet AMD and future trials.
  • AbbVie will lead the clinical development and commercialization globally.
  • REGENXBIO will participate in U.S. commercialization efforts under a mutually agreed upon plan.
  • REGENXBIO will receive $370M up front and is eligible for up to $1.38B in development, regulatory, and commercial milestones, plus tiered royalties on net sales of RGX-314 outside the U.S. and 50% of profits in the U.S.

Last Month:

Congrats to REGENXBIO and AbbVie for landing the DealForma September 2021 Deal of the Month. The Deal of the Month for August 2021 was RemeGen and Seagen’s HER2 ADC deal with $200M up front for Disitamab Vedotin. Read about it here.

DealForma’s Deal of the Month selection is based on the largest disclosed upfront cash and equity total in partnership deals involving R&D as announced in the month prior to this article. Data for this analysis was compiled using the DealForma biopharma deals database. All data are based on publicly disclosed figures and deal terms.

We invite you to answer interesting questions on biopharma business development and licensing using our data and carefully curated profiles on deals, pipelines, companies, funding, and business executives by visiting dealforma.com to schedule your personalized demo.

21,598

Licensing Deals

22,217

Funding Rounds

4,216

M&A

35,278

Company Profiles

5,897

Other Deals

27,588

Drug Sales Figures

All of this by stage, disease indication, modality, target...

More Research by DealForma

Biopharma Venture Investment Through Q3 2023

Biopharma Venture Investment Through Q3 2023

Biopharma venture investment totals rebounded in Q3 2023, nearing 2020 quarterly levels. The number of rounds, especially for seed and Series A, are still depressed as we are seeing investors re-investing in later rounds of portfolio companies rather than new...

Biopharma M&A Through Q3 2023

Biopharma M&A Through Q3 2023

This is a quick readout of biopharma M&A activity through Q3 2023 as we track the prominent deals for the year leading up to year-end. Among some of the largest in biopharma are Novo Nordisk's acquisition of Inversago Pharma offering shareholders up to $1.075...

Biopharma R&D Partnerships – Q3 2023 Review

Biopharma R&D Partnerships – Q3 2023 Review

Biotech, pharma, and medtech R&D partnerships in Q3 2023 settled to pre-2020 levels on total deal announced values but again on fewer deals. Major deal announcements in Q3 included Pfizer / Flagship Pioneering, Alnylam / Roche, Nanobiotix / Janssen, Orionis /...